echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > The bifunctional fusion protein targeting PD-L1/TGF-β was approved by the FDA

    The bifunctional fusion protein targeting PD-L1/TGF-β was approved by the FDA

    • Last Update: 2021-06-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit

    Article source: Pharmaceutical Guanlan

    On June 2nd, Boji Biomedical Technology (Hangzhou) Co.
    , Ltd.
    (hereinafter referred to as Boji Bio) recently announced that the US FDA approved its self-developed PD-L1/TGF-β bifunctional fusion protein (code name: BJ- 005) New Drug Clinical Trial Application (IND), which can carry out clinical trials in the United States

    This is the second independent research and development product approved by the FDA after the tumor-targeting IL-15 fusion protein (BJ-001) was approved for clinical use in the United States in 2019


    BJ-005 is a recombinant dual-function fusion of a humanized anti-programmed death ligand 1 (PD-L1) IgG1 monoclonal antibody and a part of the extracellular domain of human transforming growth factor β (TGF-β) receptor II The fusion protein can simultaneously target PD-L1 and TGF-β, inhibit tumor growth by targeting immune checkpoints and regulating tumor cell growth cytokine pathways, and is used to treat cancer patients

    Note: The original text has been deleted

    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.